Hexos 75mg/ml 10ml Vial by Driada Medical

Usage

1. Confirm your blast-phase start date and set a calendar-based injection schedule — twice-weekly spacing (e.g. Monday/Thursday) maintains steady plasma exposure throughout the blast window.
2. Draw your Hexos dose using a 21–23g needle for withdrawal from the 10ml vial; swap to a 23–25g needle for intramuscular injection to minimise injection-site discomfort across the multi-week blast phase.
3. Rotate injection sites (glutes, laterals, delts) systematically across each blast phase to prevent tissue irritation from repeated trenbolone hexahydrobenzylcarbonate administration at the same location.
4. Pair Hexos blast-phase dosing with a testosterone base compound — the testosterone maintains baseline androgen function while the hexahydrobenzylcarbonate ester provides the primary anabolic stimulus.
5. At the close of the blast phase, cease Hexos injections and allow the ester to clear; schedule blood work (haematocrit, ALT, AST, lipid panel) two to four weeks after the final injection to evaluate cruise-phase readiness.
6. Store the remaining vial contents in a cool, dark location at 8–15°C; use a fresh, capped needle for each draw to maintain septum sterility across the full 10ml volume.

Warnings

Frequently asked questions

What does a cruise and blast protocol actually involve when using Trenbolone Hexahydrobenzylcarbonate?

A cruise and blast protocol alternates between a high-dose blast phase — where a potent compound like Trenbolone Hexahydrobenzylcarbonate is added at performance doses — and a cruise phase where only a maintenance testosterone dose is maintained. Trenbolone Hexahydrobenzylcarbonate suits the blast role because its extended ester provides weeks of sustained exposure, then tapers gradually, easing the transition into cruise without an abrupt hormonal drop.

How long should the blast phase with Hexos 75mg/ml typically last before switching to cruise?

Most structured blast phases using Trenbolone Hexahydrobenzylcarbonate run eight to twelve weeks, after which the compound is discontinued while testosterone is maintained at cruise levels. The hexahydrobenzylcarbonate ester's slow clearance means plasma Trenbolone concentrations decline over several weeks following the last Hexos injection, creating a natural taper into the cruise phase without requiring additional intervention.

When during a blast-to-cruise switch should blood work be run to assess Hexos cycle safety?

Blood work covering haematocrit, ALT, AST, and a fasted lipid panel should be run approximately two to four weeks after the final Hexos injection in a blast phase — once trenbolone levels have sufficiently cleared — to capture the true post-blast baseline. This data informs whether the cruise phase duration needs extending before the next blast is initiated, based on individual biomarker recovery.

Why is 75mg/ml a useful concentration specifically for cruise and blast dosing adjustments?

The 75mg/ml concentration in Hexos allows more granular dose titration compared to 100mg/ml preparations, which matters when scaling Trenbolone exposure up at the start of a blast or tapering it progressively at the close. At 75mg/ml, each 0.5ml increment equals 37.5mg — a practical unit for weekly dose adjustments without rounding to unworkable volumes or concentrations.

How should a 10ml Hexos vial be stored after first use and how long does it remain viable?

After first puncture, Hexos should be stored in a cool, dark environment — ideally between 8°C and 15°C — away from direct light, which can degrade the ester. The rubber septum maintains sterility across multiple draws when accessed with a fresh needle each time. Driada Medical's batch documentation specifies the use-by date per lot; in practice, a 10ml vial used at twice-weekly dosing is typically exhausted within five to six weeks of first access, well within the stability window. (2) angle_used

Manufacturer

Driada Medical's approach to product authentication operates at the point of batch release rather than purely at the point of sale — a structural difference from brands whose verification systems begin only once the product has left their warehouse. Each Hexos lot is assigned a serialised identifier that links the physical vial to its corresponding HPLC chromatogram, LAL endotoxin result, and sterility certificate; that identifier is encoded into the holographic tamper-evident label applied to the vial before dispatch. End users can cross-reference the hologram code against Driada Medical's batch verification registry, which returns the specific analytical results for that production run — not a generic certificate of analysis, but the chromatographic output and endotoxin value recorded for the exact lot in hand. This traceability architecture is particularly relevant to Hexos given that the 75mg/ml concentration is a precise formulation target: independent users running third-party mass-spectrometry checks against declared concentration can use the registered batch data as the reference baseline, enabling meaningful comparison rather than verification against an unlabelled claim.